Ultragenyx Pharmaceutical Inc Net Income per Employee (RARE), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Ultragenyx Pharmaceutical Inc   (NASDAQ: RARE)
 

Ultragenyx Pharmaceutical Inc Net Income per Employee

RARE's Quarterly Results, Trends, Rankings, Statistics
Ultragenyx Pharmaceutical Inc recorded a cumulative net loss of $-609 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 134 other companies achieving higher income per employee. While Ultragenyx Pharmaceutical Inc 's total ranking has deteriorated compared to the previous quarter from 3240 to 3394.


What is Income per Employee Ratio?






RARE Net Income per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -444,143 -419,402 -422,924 -388,718 -400,860
RARE's Total Ranking # 3394 # 3240 # 1244 # 2727 # 2659
Seq. Net Income Change - - - - -


RARE Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 135
Healthcare Sector # 435
Overall Market # 3394

Net Income per Employee Statistics
High Average Low
$ -106,213 $ -297,936 $ -525,703
(Dec 31 2015)   (Jun 30 2023)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-30T14:42:55+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.